SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    LiVolsi VA, Albores-Saavedra J, Asa SL, et al. Papillary carcinoma. In: DeLellisRA, LloydRV, HeitzPU, EngC, eds. World Health Organization Classification of Tumours Pathology & Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004: 5766.
  • 2
    Sobrinho Simoes M, Asa SL, Kroll TG, et al. Follicular carcinoma. In: DeLellisRA,LloydRV, HeitzPU, EngC, eds. World Health Organization Classification of Tumours Pathology & Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004: 6776.
  • 3
    Dahl PR, Broadland DG, Goellner JR, et al. Thyroid carcinoma metastatic to the skin: a cutaneous manifestation of widely disseminated disease. J Am Acad Dermatol. 1997; 36: 531537.
  • 4
    Alwaheeb S, Ghazarian D, Boerner SL, et al. Cutaneous manifestations of thyroid cancer: a report of four cases and review of the literature. J Clin Pathol. 2004; 57: 435438.
  • 5
    Lissak B, Vannetzel JM, Gallouedec N, et al. Solitary skin metastasis as the presenting feature of differentiated thyroid microcarcinoma: report of two cases. J Endocrinol Invest. 1995; 18: 813816.
  • 6
    Quinn TR, Duncan LM, Zembowicz A, Faquin WC. Cutaneous metastases of follicular thyroid carcinoma: a report of four cases and a review of the literature. Am J Dermatopathol. 2005; 27: 306312.
  • 7
    Boughattas S, Hassine H, Chatti K, Jomaa R, Essabbah H. Cutaneous metastasis revealing a widely disseminated follicular thyroid carcinoma. Clin Nucl Med. 2002; 27: 379380.
  • 8
    Koller EA, Tourtelot JB, Pak HS, Cobb MW, Moad JC, Flynn EA. Papillary and follicular thyroid carcinoma metastatic to the skin: a case report and review of the literature. Thyroid. 1998; 8: 10451050.
  • 9
    Toyota N, Asaga H, Hirokawa M, Iizuka H. A case of skin metastasis from follicular thyroid carcinoma. Dermatology. 1994; 188: 6971.
  • 10
    Pitlik S, Kitzes R, Ben-Bassat M, Rosenfeld JB. Thyroid carcinoma presenting as a solitary skin metastasis. Cutis. 1983; 31: 532536.
  • 11
    Horiguchi Y, Takahashi C, Imamura S. Cutaneous metastasis from papillary carcinoma of the thyroid gland. Report of two cases. J Am Acad Dermatol. 1984; 10: 988992.
  • 12
    Tronnier M, Winzer M, Wolff HH. Cutaneous metastases from follicular thyroid carcinoma: histology, immunohistology, and electron microscopy. A report of two cases. Dermatologica. 1991; 183: 286289.
  • 13
    Doutre MS, Beylot C, Baquey A, et al. Cutaneous metastasis from papillary carcinoma of the thyroid. A case confirmed by monoclonal antithyroglobulin antibody. Dermatologica. 1988; 177: 241243.
  • 14
    Elgart GW, Patterson JW, Taylor R. Cutaneous metastasis from papillary carcinoma of the thyroid gland. J Am Acad Dermatol. 1991; 25: 404408.
  • 15
    Vives R, Valcayo A, Menendez E, Guarch R. Follicular thyroid carcinoma metastatic to the skin. J Am Acad Dermatol. 1992; 27: 276277.
  • 16
    Caron P, Moreau-Cabarrot A, Gorguet B, Bazex J. Cutaneous metastasis from follicular carcinoma of the thyroid gland. Thyroid. 1993; 3: 235237.
  • 17
    Loureiro MM, Leite VH, Boavida JM, et al. An unusual case of papillary carcinoma of the thyroid with cutaneous and breast metastases only. Eur J Endocrinol. 1997; 137: 267269.
  • 18
    Hoie J, Stenwig AE, Kullmann G, et al. Distant metastases in papillary thyroid cancer: a review of 91 patients. Cancer 1988; 177: 241243.
  • 19
    Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949954.
  • 20
    Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001; 93: 5362.
  • 21
    Marais R, Marshall CJ. Control of the ERK MAP kinase cascade by Ras and Raf. Cancer Surv. 1996; 27: 101125.
  • 22
    Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003; 95: 625627.
  • 23
    Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005; 24: 66466656.
  • 24
    Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003; 63: 14541457.
  • 25
    Nakamura N, Carney JA, Jin L, et al. RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors. Lab Invest. 2005; 85: 10651075.
  • 26
    Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88: 53995405.
  • 27
    Sedliarou I, Saenko V, Lantsov D, et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int J Oncol. 2004; 6: 17291735.
  • 28
    Trovisco V, Soares P, Preto A, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch. 2005; 446: 589595.
  • 29
    Xu X, Ouiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003; 63: 45614567.
  • 30
    French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol. 2003; 62: 10531060.
  • 31
    Carcangiu ML, Sibley RK, Rosai J. Clear cell change in primary thyroid tumors. A study of 38 cases. Am J Surg Pathol. 1985; 9: 705722.
  • 32
    Volmar KE, Cummings TJ, Wang WH, Creager AJ, Tyler DS, Xie HB. Clear cell hidradenoma: a mimic of metastatic clear cell tumors. Arch Pathol Lab Med. 2005; 129: 113116.
  • 33
    Zelger BW, Steiner H, Kutzner H. Clear cell dermatofibroma: case report of an unusual fibrohistiocytic lesion. Am J Surg Pathol. 1995; 20: 483491.
  • 34
    Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma. A retrospective study of 7316 cancer patients. J Am Acad Dermatol. 1990; 22: 1926.
  • 35
    Begum S, Rosenbaum E, Henrique R, et al. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod Pathol. 2004; 17: 13591363.
  • 36
    Ciampi R, Zhu Z, Nikiforov YE. BRAF copy number gains in thyroid tumors detected by fluorescence in situ hybridization. Endocr Pathol. 2005; 16: 99105.
  • 37
    Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005; 90: 6373363739.